Please use this identifier to cite or link to this item:
|標題:||Combined Use of Zoledronic Acid Augments Ursolic Acid-Induced Apoptosis in Human Osteosarcoma Cells through Enhanced Oxidative Stress and Autophagy||作者:||Wu, Chia-Chieh
|關鍵字:||osteosarcoma;ursolic acid;zoledronic acid;Antineoplastic Agents;Apoptosis;Autophagy;Cell Line, Tumor;Cell Proliferation;Cell Survival;Diphosphonates;Drug Screening Assays, Antitumor;Drug Synergism;Humans;Imidazoles;Osteosarcoma;Reactive Oxygen Species;Triterpenes;Oxidative Stress||Project:||Molecules (Basel, Switzerland), Volume 21, Issue 12||摘要:||
Ursolic acid (UA), a naturally occurring pentacyclic triterpene acid found in many medicinal herbs and edible plants, triggers apoptosis in several tumor cell lines but not in human bone cancer cells. Most recently, we have demonstrated that UA exposure reduces the viability of human osteosarcoma MG-63 cells through enhanced oxidative stress and apoptosis. Interestingly, an inhibitor of osteoclast-mediated bone resorption, zoledronic acid (ZOL), also a third-generation nitrogen-containing bisphosphonate, is effective in the treatment of bone metastases in patients with various solid tumors. In this present study, we found that UA combined with ZOL to significantly suppress cell viability, colony formation, and induce apoptosis in two lines of human osteosarcoma cells. The pre-treatment of the antioxidant had reversed the oxidative stress and cell viability inhibition in the combined treatment, indicating that oxidative stress is important in the combined anti-tumor effects. Moreover, we demonstrated that ZOL combined with UA significantly induced autophagy and co-administration of autophagy inhibitor reduces the growth inhibitory effect of combined treatment. Collectively, these data shed light on the pathways involved in the combined effects of ZOL and UA that might serve as a potential therapy against osteosarcoma.
|Appears in Collections:||生物醫學研究所|
Show full item record
TAIR Related Article
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.